US OptionsDetailed Quotes

SLS250117C2000

Watchlist
  • 0.10
  • +0.04+66.67%
15min DelayClose Dec 26 16:00 ET
0.10High0.06Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    Dec 10 07:57
    NEWS
    $Sellas Life Sciences (SLS.US)$
    SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
    Tuesday, 10th December at 8:30 am
    -  Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –
    -  REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -
    -  Company to Host Webcast Call Today at 9:00 am ET
    NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: ...
    Trytosaveabit
    Trytosaveabit
    Dec 9 07:47
    Update
    $Sellas Life Sciences (SLS.US)$ SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
    2 MINUTES AGO, 8:45 AM EST
    VIA GLOBENEWSWIRE
    Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
    - Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Relat...
    Jaguar8
    Jaguar8
    Dec 9 07:45
    NEWS
    $Sellas Life Sciences (SLS.US)$
    SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
    Monday, 9th December at 8:45 am
    - Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
    - Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AM...
    Jaguar8
    Jaguar8
    Dec 8 16:31
    SLS presenting in ASH Conference
    $Sellas Life Sciences (SLS.US)$
    “SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses”
    Trytosaveabit
    Trytosaveabit
    Nov 27 07:50
    Update
    $Sellas Life Sciences (SLS.US)$ Reuters· 2 mins ago
    Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies
Read more